<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409222580
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CISPLATIN 0.5MG-ML INJ.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CISPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for dispersion for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        72.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cisplatin forms part of a group of medicines called cytostatics, which are used in the treatment of cancer. Cisplatin can be used alone but more commonly Cisplatin is used in combination with other cytostatics.</p><p><strong>&nbsp;</strong></p><p>Cisplatin can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary, head and neck epithelial tumour (tumour affecting the outer tissue layer of the skin), tumour in the lung).</p><p>Your doctor will be able to provide you with more information.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use CISPLATIN:</strong></p><ul><li>if you are allergic to cisplatin or any of the other ingredients of this medicine (listed in section 6).</li><li>if you are allergic (hypersensitive) to any other medicine that contains platin</li><li>if you have kidney problems (renal dysfunction)</li><li>if you suffer from dehydration</li><li>if you suffer from decrease in blood cell count</li><li>if your hearing impaired</li><li>if you are breastfeeding</li><li>combined with yellow vaccine and phenytoin (see &ldquo;Use of Cisplatin with other medicines&rdquo; below).</li></ul><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using CISPLATIN.</p><p>&nbsp;</p><ul><li>Your doctor will carry out tests in order to determine the levels of calcium, sodium, potassium and magnesium in your blood, as well as to check your blood cell count and your liver and kidney function.</li><li>Cisplatin should only be administered under the strict supervision of a specialist doctor experienced in administrating chemotherapy.</li><li>Your hearing will be tested prior to each treatment with Cisplatin.</li><li>If you suffer from a nervous disorder not caused by Cisplatin.</li><li>If you suffer from an infection. Please consult your doctor.</li><li>If you suffer from vomiting and diarrhoea after administration of Cisplatin the liquid loss must be compensated.</li><li>If you intend to have children (see Pregnancy, breast-feeding and fertility).</li><li>With spillage of ciplatin the contaminated skin must immediately be washed with water and soap.</li></ul><p>&nbsp;</p><p>Please consult your doctor, even if these statements were applicable to you at any time in the past.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and CISPLATIN</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>&nbsp;</p><ul><li>Simultaneous use of medicines that inhibit the bone marrow function or radiation can potentiate the adverse effects of cisplatin on the bone marrow.</li><li>Cisplatin toxicticity may increase when administered simultaneously with other cytostatics (medicine for cancer treatment), such as bleomycin and methotrexate .</li><li>Agents to treat high blood pressure (antihypertensives containing furosemide, hydralazine, diazoxide, and propranolol) may increase the toxic effect of Cisplatin on kidneys.</li><li>Cisplatin toxicity may severely affect the kidneys when administered simultaneously with agents that may cause side effects in the kidneys, such as those for the prevention/treatment of certain infections (antibiotics: cephalosporins, aminoglycosides, and/or amphotericin B) and contrast agents.</li><li>Cisplatin toxicity may affect hearing abilities when administered simultaneously with agents that may have a side effect on hearing faculties, such as aminoglycosides.</li><li>If you use agents to treat gout during your treatment with cisplatin, then the dosage of such agents may need to be adjusted (e.g. allopurinol, colchicine, probenecid and/or sulfinpyrazone).</li><li>Administration of drugs that elevate your rate of bodily urine excretion (loop diuretics) combined with cisplatin (cisplatin dose: more than 60mg/m&sup2;, urine secretion: less than 1000 ml per 24 hours) may result in toxic effects on kidneys and hearing.</li><li>The first signs of hearing damage (dizziness and/or tinnitus) may remain hidden when &ndash; during your treatment with cisplatin &ndash; you are also being administered agents to treat hypersensitivity (antihistamines, such as buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes and/or trimethobenzamides).</li><li>Cisplatin given in combination with ifosphamide may result in hearing impairment or toxic effect on kidneys.</li><li>The effects of treatment with cisplatin can be reduced through simultaneous administration of pyridoxine and hexamethylmelamine.</li><li>Cisplatin given in combination with bleomycin and vinblastin may result in paleness or blue coloration of the fingers and/or toes (Raynaud`s phenomenon).</li><li>Administration of cisplatin for treatment with paclitaxel or in combination with docetaxel may result in severe nerve damage.</li><li>The combined use of cisplatin with bleomycin and etoposide may decrease lithium levels in the blood. Therefore, lithium levels should be checked on a regular basis.</li><li>Cisplatin reduces the effects of phenytoin on the treatment of epilepsy (also see &ldquo;Do not use Cisplatin&rdquo;).</li><li>Cisplatin may have an adverse impact on the effectivity of agents preventing coagulation (anticoagulants). Therefore, coagulation should be checked more often during combined use.</li><li>Cisplatin and ciclosporin may result in suppression of the immune system with the risk of increased production of white blood cells (lymphocytes).</li><li>You should not receive any vaccinations containing live viruses within three months of treatment with cisplatin.</li><li>When undergoing treatment with Cisplatin, you must not receive yellow fever vaccinations (also see &ldquo;Do not use Cisplatin&rdquo;).</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p>Cisplatin should not be used during <strong>pregnancy </strong>unless it is clinically necessary for the mother.</p><p><strong>You must use effective contraception during and at least 6 months after treatment with Cisplatin. </strong>Cisplatin must not be used while <strong>breast-feeding</strong>.</p><p>&nbsp;</p><p><strong>Male patients treated with Cisplatin are advised not to father a child during treatment and for up to 6 months after treatment. </strong>Further, men are advised to seek counseling on sperm preservation before starting treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use any tools or machinery that require your full attention, because cisplatin may make you feel sleepy and/or cause vomiting.</p><p>&nbsp;</p><p><strong>CISPLATIN contains sodium</strong>.</p><p>This medicine contains 71 mg sodium (main component of cooking salt) in each 20ml vial. This is equivalent to 3.55% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>This medicine contains 177 mg sodium (main component of cooking salt) in each 50ml vial. This is equivalent to 8.85% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>This medicine contains 354 mg sodium (main component of cooking salt) in each 100ml vial.</p><p>This is equivalent to 17.7% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage and method of administration</p><p>Cisplatin should only be given by a specialist in cancer treatment. The concentrate is diluted with a sodium chloride solution, or a sodium chloride solution that contains glucose, or a sodium chloride solution that contains mannitol.</p><p>&nbsp;</p><p>Cisplatin is only given by infusion into a vein (an intravenous infusion).</p><p>&nbsp;</p><p>Cisplatin should not come into contact with any materials that contain aluminium.</p><p>&nbsp;</p><p>The recommended dosage of Cisplatin depends on your well-being, the anticipated effects of the treatment, and whether or not cisplatin is given on its own (monotherapy) or in combination with other agents (combination chemotherapy).</p><p>&nbsp;</p><p><u>Cisplatin 0.5 mg/ml (monotherapy):</u></p><p>The following dosages are recommended:</p><p>-&nbsp;&nbsp;&nbsp; A <em>single</em> dosage of 50 to 120 mg/m&sup2; body surface, every 3 to 4 weeks</p><p>-&nbsp;&nbsp;&nbsp; 15 to 20 mg/m&sup2; per day over a 5-day period, every 3 to 4 weeks</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cisplatin 0.5 mg/ml in combination </u></p><p><u>with other chemotherapeutical agents (combination chemotherapy):</u></p><p>- The typical dosage is 20 mg/m&sup2; or more, every 3 to 4 weeks</p><p>- In the treatment of tumours in the lung the typical dosage is 80 mg/m&sup2;</p><p>&nbsp;</p><p>In order to avoid, or reduce, kidney problems, you are advised to drink copious amounts of water for a period of 24 hours following treatment with Cisplatin.</p><p>&nbsp;</p><p><strong>If you believe you have received more Cisplatin than you should</strong></p><p>Your doctor will ensure that the correct dose for your condition is given. In case of overdose, you may experience increased side effects. Your doctor may give you symptomatic treatment for these side effects.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact your doctor as soon as possible if:</p><ul><li>you have persistent or severe diarrhea or vomiting</li><li>you have stomatitis/mucositis (sore lips or mouth ulcer)</li><li>you have swelling of the face, lips mouth or throat</li><li>you have unexplained respiratory symptoms such as non-productive cough, difficulty in breathing or crackles</li><li>you have difficulty in swallowing</li><li>you have numbness or tingling in your fingers or toes</li><li>you have extreme tiredness</li><li>you have abnormal bruising or bleeding</li><li>you have signs of infection, such as sore throat and high temperature</li><li>you have sensation of discomfort close to or at the injection site during the infusion.</li><li>you have severe pain or swelling in either of your legs, chest pain, or difficulty breathing (possibly indicating harmful blood clots in a vein) (common: may affect up to 1 in every 10&nbsp;people)</li></ul><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><ul><li>reduction in the number of white blood cells, which makes infections more likely (leukopenia)</li><li>reduction in blood platelets, which increases the risk of bruising and bleeding (thrombocytopenia)</li><li>reduction in red blood cells, which can make the skin pale and cause weakness or breathlessness (anaemia)</li><li>bone marrow failure (no production of blood cells)</li><li>low levels of sodium in the blood</li></ul><ul><li>fever</li></ul><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>sepsis</li><li>arrhythmia, including reduced heartbeat (bradycardia), accelerated heartbeat (tachycardia).</li><li>shortness of breath (dyspnoea), inflammation of the lungs (pneumonia) and respiratory failure</li></ul><p>&nbsp;</p><p><strong>Uncommon </strong><strong>(may affect up to 1 in 100 people)</strong></p><p>&nbsp;</p><ul><li>decreased production of sperm (dysfunctional spermatogenesis) and ovulation, and painful breast growth in men (gynaecomastia).</li><li>acute leukemia</li><li>low blood levels of magnesium (hypomagnesemia)</li><li>damage of hearing (ototoxicity)</li><li>metallic setting on the gums</li></ul><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>various diseases of the brain (leukoencephalopathy)</li><li>High levels of cholesterol in the blood (hypercholesterolaemia)</li><li>convulsion</li><li>numbness, tingling, burning (peripheral neuropathy)</li><li>abnormal changes in the brain that can cause a collection of symptoms including headache, confusion, seizures, and vision loss associated with MRI imaging findings (reversible posterior leukoencephalopathy syndrome)</li><li>heart attack</li><li>inflammation of mucous membranes of the mouth (stomatitis).</li></ul><p>&nbsp;</p><p><strong>Very rare (</strong><strong>may affect up to 1 in 10,000 people)</strong></p><ul><li>increased iron levels in the blood</li><li>&nbsp;</li><li>heart stops pumping blodd (cardiac arrest)</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>infection</li><li>destruction of red blood cells (Coombs positive hemolytic anemia)</li><li>certain enzyme increased (amylase)</li><li>group of symptoms that develop when there is too much antidiuretic hormone (ADH) in the body like water retention, electrolyte imbalances and a low level of sodium in the blood (called hyponatremia or water intoxication)</li><li>dehydration</li><li>low levels of electrolytes in the blood (potassium, phosphate, calcium)</li><li>increased blood level of uric acid, a waste material from food digestion</li><li>muscle cramps (tetany)</li><li>stroke</li><li>loss of taste</li><li>inflammation of blood vessels in the brain</li><li>sudden shooting pains from the neck through the back into the legs when bending forwards (Lhermitte&rsquo;s sign)</li><li>spinal cord compression (myelopathy)</li><li>damage of nerves which control involuntary bodily functions (may effect blood pressure, temperature control, digestion, bladder function)</li><li>blurred vision</li><li>color blindness</li><li>loss of sight (blindness)</li><li>inflammation of the optic nerve</li><li>swelling around the nerve responsible for sight (papilledema)</li><li>pigmentation of the retina (a multi-layered sensory tissue that lines the back of the eye responsible for sight)</li><li>noise in the ears, such as ringing, buzzing, roaring, clicking</li><li>deafness</li><li>&nbsp;problems with the heart</li><li>Collection of signs including hemolytic anemia (destruction of red blood cells), kidney failure and a low platelet (a type of blood cell that helps to clot blood) count (hemolytic uremic syndrome)</li><li>pale and blue-colored fingers and toes (Raynaud&rsquo;s phenomenon)</li><li>feeling sick (nausea) and vomiting</li><li>loss of appetite</li><li>hiccups</li><li>diarrhea</li><li>enzymes in the blood increased which could be a sign of liver damage</li><li>blood clot in the lungs</li><li>Rash</li><li>loss of hair<em> </em>(alopecia)</li><li>muscle spasms</li><li>decrease or complete loss of kidney function</li><li>weakness, loss of energy</li><li>redness, inflammation, swelling of the skin and pain in the area of the injection as a result of injection in the surrounding tissue instead of the vein</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 25&deg;C.</p><p>Do not refrigerate or freeze.</p><p>Keep the vial in the outer carton<strong><em> </em></strong>in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial<strong><em> </em></strong>after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice visible signs of deterioration.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each millilitre (ml) of solution contains 0.5 milligram (mg) of cisplatin.</p><p>The 20 ml vial contains 10 mg cisplatin, the 50 ml vial contains 25 mg cisplatin and the 100 ml vial contains 50 mg cisplatin.</p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>The active substance is</u> cisplatin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other ingredients are</u> sodium chloride, dilute hydrochloric acid and water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cisplatin is a clear and colourless to yellowish solution for infusion in glass injection vials. 
Packaging with 1 injection vial of 20 ml, each injection vial containing 10 mg cisplatin.
Packaging with 1 injection vial of 50 ml, each injection vial containing 25 mg cisplatin.
Packaging with 1 injection vial of 100 ml, each injection vial containing 50 mg cisplatin.

Not all pack sizes may be marketed.

The vials are packed with or without a protective plastic overwrap (OncoSafe®).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُشكل عقار سِيسْبلاتين جزءًا من مجموعة من الأدوية تسمى مثبطات نمو الخلايا، والتي تستخدم في علاج السرطان. من الممكِن استخدام عقار سِيسْبلاتين بمفرده، ولكن عقار سِيسْبلاتين يُستخدم بشكل أكثر شيوعًا بمصاحبة غيره من مثبطات نمو الخلايا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بإمكان عقار سِيسْبلاتين تدمير (إتلاف) خلايا الجسم التي قد تُسبب بعض أنواع السرطان (أورام الخصيتين، ورم المبيض، ورم الظهارة في الرأس والرقبة (ورم يؤثر على طبقة الأنسجة الخارجية للجلد)، ورم بالرئة).</p><p dir="RTL">سيكون طبيبك قادرًا على تزويدك بمزيد من المعلومات.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار سِيسْبلاتين في الحالات التَّالية</strong><strong>:</strong></p><ul><li dir="RTL">إذا كنت تعاني من حساسية تجاه سِيسْبلاتين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</li><li dir="RTL">إذا كنت تعاني من حساسية (فرط حساسية) تجاه أي دواء آخر يحتوي على البلاتين</li><li dir="RTL">إذا كنت تعاني من مشاكل بالكُلى (قصور وظائف الكُلى)</li><li dir="RTL">إذا كنت تُعاني من الجفاف</li><li dir="RTL">إذا كنت تعاني من انخفاض في تعداد خلايا الدم</li><li dir="RTL">إذا كنت مصابًا بضعف السمع</li><li dir="RTL">إذا كنتِ مرضعًا</li><li dir="RTL">بمصاحبة اللقاح الأصفر والفينيتوين (انظر قسم &quot;استخدام عقار سيسبلاتين مع أدوية أخرى&quot; أدناه).</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار سِيسْبلاتين.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">سيجري لك طبيبك اختبارات؛ لتحديد مستويات الكالسيوم والصوديوم والبوتاسيوم والماغنسيوم لديك في الدَّم وكذلك لفحص تعداد خلايا الدَّم ومدى كفاءة وظائف الكبد والكُلى.</li><li dir="RTL">يجب عدم إعطاء عقار سِيسْبلاتين إِلَّا تحت إشراف صارم من قِبَل طبيب متخصص من ذوي الخبرة في إعطاء العلاج الكيميائي.</li><li dir="RTL">سيتم اختبار حاسة السمع لديك قبل كل مرة تتلقى فيها العلاج بعقار سِيسْبلاتين.</li><li dir="RTL">إذا كنت تُعاني من اضطرابات عصبية ليس سببها تلقي عقار سِيسْبلاتين.</li><li dir="RTL">إذا كنت تعاني من عدوى. يُرجى استشارة طبيبك.</li><li dir="RTL">إذا كنت تعاني من قيء وإسهال بعد تناول عقار سِيسْبلاتين، يجب تعويض فقدان السوائل.</li><li dir="RTL">إذا كنت تنوي/ كنتِ تنوين الإنجاب (انظر/ انظري: الحمل، الرضاعة الطبيعيَّة والخصوبة)</li><li dir="RTL">عند انسكاب عقار سِيسْبلاتين يجب غسل الجلد الملوث على الفور بالماء والصابون.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى استشارة طبيبك، حتى لو كانت هذه الحالات تنطبق عليك في أي وقت في الماضي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>عقار سِيسْبلاتين مع الأدوية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">من الممكن أن يؤدي الاستخدام المتزامن للأدوية التي تثبط وظائف النخاع العظمي أو تلقي العلاج الإشعاعي إلى تعزيز الآثار العكسية لعقار سِيسْبلاتين على النخاع العظمي.</li><li dir="RTL">قد تزداد سمية عقار سِيسْبلاتين عند إعطائه بالتزامن مع غيره من مثبطات نمو الخلايا (دواء لعلاج السرطان)، مثل بليوميسين وميثوتريكسات.</li><li dir="RTL">قد تزيد أدوية علاج ارتفاع ضغط الدَّم (الأدوية الخافضة لضغط الدَّم والتي تحتوي على فوروسيميد وهيدرالازين وديازوكسيد وبروبرانولول) من التَّأثير السام لعقار سِيسْبلاتين على الكُلى.</li><li dir="RTL">قد تؤثر سُمية عقار سِيسْبلاتين بشدة على الكُلى عند إعطائه بالتَّزامن مع الأدوية التي قد تسبب آثارًا جانبيةً في الكُلى، مثل أدوية الوقاية من/ علاج بعض أنواع العدوى (المضادات الحيوية: السيفالوسبورينات، الأمينُوجْليكُوزيدات و/ أو أَمْفُوتيريسين &quot;بي&quot;) ومواد التباين.</li><li dir="RTL">قد تؤثر سمية عقار سِيسْبلاتين على قدرات حاسة السمع عند إعطائه بالتزامن مع أدوية قد يكون لها أثر جانبي على قوى السمع، مثل الأمينُوجْليكُوزيدات.</li><li dir="RTL">إذا كنت تستخدم أدوية لعلاج النّقْرِس أثناء خضوعك للعلاج بعقار سِيسْبلاتين، عندئذٍ قد يستلزم الأمر تعديل جرعة هذه الأدوية (على سبيل المثال: ألوبيورينول، كُولْشيسين، بروبنيسيد و/ أو سَلفينبيرازون).</li><li dir="RTL">قد يُؤدي إعطاء العقاقير التي تزيد من معدل إفراز البول لديك (مُدِرات البول العُرْوِيَّة) بمصاحبة عقار سِيسْبلاتين (جرعة عقار سِيسْبلاتين: أكثر من 60 مجم/ متر مربع، إفراز البول: أقل من 1000 مللي لتر كل 24 ساعة) إلى حدوث آثار سامة على الكُلى وحاسة السمع.</li><li dir="RTL">قد تظل العلامات الأولى لضعف السمع (الدوخة و/ أو الطنين بالأذن) مخفية إذا كنت تتلقى أيضًا عقاقير مضادة لتفاعلات فرط الحساسية أثناء علاجك بعقار سِيسْبلاتين (مضادات الهيستامين، مثل: بُوكْليزين، سِيكْليزين، لوكسابين، ميكلوزين، فينوثيازين، ثيوزانثين و/ أو تريميثوبنزاميد).</li><li dir="RTL">قد يؤدي استخدام عقار سِيسْبلاتين بمصاحبة إيفوفوسفاميد إلى ضعف حاسة السمع أو تأثير سام على الكُلى.</li><li dir="RTL">قد تنخفض تأثيرات العلاج بعقار سِيسْبلاتين عن طريق إعطاء بيريدوكسين وهكسا ميثيل ميلامين بالتَّزامن.</li><li dir="RTL">قد يُؤدي إعطاء عقار سِيسْبلاتين بمصاحبة بليوميسين وفينبلاستين إلى حدوث شحوب أو تغيُّر لون أصابع اليدين و/ أو أصابع القدمين إلى اللون الأزرق (ظاهرة رينود).</li><li dir="RTL">قد يُؤدي إعطاء عقار سِيسْبلاتين للعلاج مع باكليتاكسيل أو بمصاحبة دوسيتاكسيل إلى تلف عصبي شديد.</li><li dir="RTL">قد يُؤدي الاستخدام المُركب لعقار سِيسْبلاتين مع بليوميسين وإيتوبوسايد إلى انخفاض مستويات الليثيوم بالدَّم. لذلك، يجب التحقق من مستويات الليثيوم بانتظام.</li><li dir="RTL">يقلل عقار سِيسْبلاتين تأثيرات الفينيتوين على علاج الصَّرَع (انظر أيضًا قسم &quot;لا تتناول عقار سِيسْبلاتين في الحالات الآتية&quot;).</li><li dir="RTL">قد يكون لعقار سِيسْبلاتين تأثير عكسي على فعالية الأدوية التي تمنع تجلط الدم (مضادات التجلط). لذا، يجب التحقق من تجلط الدم في أغلب الأحيان أثناء تلقي العلاج المُرَكَّب.</li><li dir="RTL">قد يُؤدي تلقي عقار سِيسْبلاتين وسيكلوسبورين إلى تثبيط الجهاز المناعي وتشكيل خطورة تتمثل في زيادة إنتاج خلايا الدَّم البيضاء (الخلايا الليمفاوية).</li><li dir="RTL">يجب ألا تتلقى أي لقاحات تحتوي على فيروسات حية خلال ثلاثة أشهر من العلاج بعقار سِيسْبلاتين.</li><li dir="RTL">عند الخضوع للعلاج بعقار سِيسْبلاتين، يجب ألا تتلقى لقاحات الحمى الصفراء (انظر أيضًا &quot;لا تستخدم عقار سِيسْبلاتين في الحالات الآتية&quot;).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب استخدام عقار سِيسْبلاتين أثناء <strong>الحمل</strong> ما لم يكن استخدامه ضروريًّا من الناحية السريرية بالنسبة للأم.</p><p dir="RTL"><strong>يجب عليكِ استخدام وسائل منع الحمل الفعَّالة أثناء العلاج وبعد </strong><strong>6 أشهر على الأقل من العلاج بعقار سِيسْبلاتين</strong><strong>. </strong>يجب عدم استخدام عقار سِيسْبلاتين أثناء<strong> الرضاعة الطبيعيَّة</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُنصَح المرضى من الذكور الذين عولجوا بعقار سِيسْبلاتين بعدم الإنجاب أثناء العلاج ولمدة تصل إلى</strong><strong> 6 </strong><strong>أشهر بعد العلاج</strong><strong>. </strong>علاوة على ذلك، يُنصح الرجال بطلب المشورة بشأن حفظ الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تمارس القيادة أو تستخدم أي أدوات أو آلات تتطلب انتباهك الكامل، لأن عقار سِيسْبلاتين قد يجعلك تشعر بالنعاس و/ أو يسبب القيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار سِيسْبلاتين على الصوديوم</strong><strong>.</strong></p><p dir="RTL">يحتوي هذا الدَّواء على 71 مجم صوديوم (المكون الرئيسي لملح الطعام) بكل عبوة زجاجية بحجم 20 مللي لترًا. وهذا يعادل 3.55٪ من الحد الأقصى الموصى بتناوله من الصوديوم يوميًّا للشخص البالغ.</p><p dir="RTL">يحتوي هذا الدَّواء على 177 مجم صوديوم (المكون الرئيسي لملح الطعام) بكل عبوة زجاجية بحجم 50 مللي لترًا. وهذا يعادل 8.85٪ من الحد الأقصى الموصى بتناوله من الصوديوم يوميًّا للشخص البالغ.</p><p dir="RTL">يحتوي هذا الدَّواء على 354 مجم صوديوم (المكون الرئيسي لملح الطعام) بكل عبوة زجاجية بحجم 100 مللي لتر.</p><p dir="RTL">وهذا يعادل 17.7٪ من الحد الأقصى الموصى بتناوله من الصوديوم يوميًّا للشخص البالغ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة وطريقة الإعطاء</strong></p><p dir="RTL">يجب عدم إعطاء عقار سِيسْبلاتين إلا من قِبَل طبيب متخصص في علاج السرطان. يتم تخفيف المحلول المُركز بمحلول كلوريد الصوديوم، أو محلول كلوريد الصوديوم الذي يحتوي على الجلوكوز، أو محلول كلوريد الصوديوم الذي يحتوي على مانيتول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتم إعطاء عقار سِيسْبلاتين إلا عن طريق التسريب داخل الوريد (التسريب الوريدي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أَلَّا يُلامس عقار سِيسْبلاتين أي مواد تحتوي على الألومنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد الجرعة المُوصى بها من عقار سِيسْبلاتين على حالتك الصحية والتأثيرات المتوقعة للعلاج، وما إذا كان عقار سِيسْبلاتين يُعطى بمفرده (كعلاج أحادي) أو بمصاحبة أدوية أخرى (علاج كيميائي مركب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>سِيسْبلاتين </u><u>0.5 مجم</u><u>/مللي لتر </u><u>(علاج أحادي</u><u>):</u></p><p dir="RTL">يوصى بتلقي الجرعات التَّالية:</p><p dir="RTL"><strong><em>-&nbsp;&nbsp;&nbsp; </em></strong><em>جرعة واحدة</em> تتراوح بين 50 و120 مجم/ متر مربع من مساحة سطح الجسم كل 3 إلى 4 أسابيع</p><p dir="RTL"><strong><em>-&nbsp;&nbsp;&nbsp; </em></strong>15 إلى 20 مجم/ متر مربع في اليوم على مدار 5 أيام، كل 3 إلى 4 أسابيع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>سِيسْبلاتين </u><u>0.5 مجم</u><u>/مللي لتر </u></p><p dir="RTL"><u>بمصاحبة أدوية العلاج الكيميائي الأخرى </u><u>(العلاج الكيميائي المُركب</u><u>):</u></p><p dir="RTL">- تكون الجرعة النموذجية 20 مجم/ متر مربع أو أكثر مرّة واحدة كل 3 إلى 4 أسابيع</p><p dir="RTL">- في علاج الأورام الموجودة في الرئة، تبلغ الجرعة النموذجية 80 مجم/ متر مربع</p><p dir="RTL">&nbsp;</p><p dir="RTL">لتجنب الإصابة بمشاكل الكُلى أو تقليل حدوثها، يتم نُصحك بشرب كميات كافية من الماء لمدة 24 ساعة بعد تلقي العلاج بعقار سِيسْبلاتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعتقد أنك قد تلقيت كمية أكبر مما يجب من عقار سِيسْبلاتين</strong></p><p dir="RTL">سيضمن طبيبك أنه قد تم إعطاؤك الجرعة الصحيحة لحالتك. في حال تلقي جرعة زائدة، قد تتعرَّض لزيادة الآثار الجانبية. قد يعطيك طبيبك علاج الأعراض المناسب لهذه الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك في أسرع وقت ممكن في الحالات الآتية:</p><ul><li dir="RTL">إذا كان لديك إِسْهال أو قيء مستمر أو شديد</li><li dir="RTL">إذا كان لديك التهاب الفم/ التهاب الغشاء المخاطي (التهاب الشفتين أو قُرَح الفم)</li><li dir="RTL">إذا كان لديك تورُّم الوجه أو الشفتين أو الفم أو الحَلْق</li><li dir="RTL">إذا كان لديك أعراض غير مُبَررة في الجهاز التَّنفسي مثل: السُّعال الجاف، أو صعوبات التنفس أو خشخشة</li><li dir="RTL">إذا كان لديك صعوبة في البلع</li><li dir="RTL">إذا كان لديك خدر أو وخز في أصابع يديك أو قدميك</li><li dir="RTL">إذا كان لديك تعب شديد</li><li dir="RTL">إذا كان لديك تكدُّم أو نزيف غير طبيعي</li><li dir="RTL">إذا كان لديك علامات الإصابة بعدوى مثل التهاب الحَلْق وارتفاع درجة الحرارة</li><li dir="RTL">إذا كان لديك إحساس بالانزعاج بالقرب من أو في موضع الحَقْن أثناء التَّسريب.</li><li dir="RTL">إذا كنت تُعاني من ألم أو تَورُّم شديد بإحدى ساقيك، ألم بالصدر، أو صعوبة في التنفس (ربما يشير ذلك إلى وجود جلطات دم ضارة في أحد الأوردة) (شائعة: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</li></ul><p dir="RTL">&nbsp;</p><p><strong>شائعة جدًّا (قد تُؤثر في أكثر من شخص واحد من كل 10 أشخاص)</strong></p><ul><li dir="RTL">انخفاض ملحوظ في عدد خلايا الدَّم البيضاء، والتي تجعلك أكثر عرضة للعدوى (قلَّةُ كرَيَّاتِ الدم البيْضاء)</li><li dir="RTL">انخفاض في عدد صفائح الدَّم، مما يزيد من خطر الإصابة بالكدمات والنزيف (نقص الصَّفائح الدَّموية)</li><li dir="RTL">انخفاض في خلايا الدَّم الحمراء، مما قد يجعل الجلد شاحبًا ويسبب ضعفًا أو عُسْر التَّنَفُّس (فقر الدَّم)</li><li dir="RTL">فشل النخاع العظمي (عدم إنتاج خلايا الدم)</li><li dir="RTL">انخفاض مستويات الصوديوم بالدم</li></ul><ul><li dir="RTL">الحمّى</li></ul><p>&nbsp;</p><p><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من كل 10&nbsp;أشخاص)</strong></p><ul><li dir="RTL">تعفن الدَّم</li><li dir="RTL">اضطرابات النظم القلبي، بما في ذلك انخفاض ضربات القلب (بطء ضربات القلب)، سرعة ضربات القَلْب (تسارع ضربات القَلْب).</li><li dir="RTL">ضيق النفس (ضيق التَّنفس)، التهاب بالرئتين (التهاب رئوي) وفشل الجهاز التّنفسي</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong><strong>(قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>100 شخص</strong><strong>)</strong></p><ul><li dir="RTL">انخفاض إنتاج الحيوانات المنوية (خلل في تكوين الحيوانات المنوية) والتبويض، ونمو مؤلم للثدي لدى الرجال (تثدّي الرجال).</li><li dir="RTL">سرطان الدم الحاد</li><li dir="RTL">انخفاض مستويات الماغنسيوم في الدَّم</li><li dir="RTL">تلف حاسة السمع (تسمم الأذن)</li><li dir="RTL">تكون رواسب معدنية على اللثة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة </strong><strong>(قد تُؤثر على ما يصل إلى شخص واحد من كل </strong><strong>1000 شخص</strong><strong>)</strong></p><ul><li dir="RTL">أمراض مختلفة بالمخ (اعْتِلالُ بَيضاءِ الدِّماغِ)</li><li dir="RTL">ارتفاع مستويات الكوليسترول في الدَّم (فرط كوليسترول الدَّم)</li><li dir="RTL">اختلاجات (تشنجات)</li><li dir="RTL">تنميل، وخز، حرق (اعتلال الأعصاب الطرفية)</li><li dir="RTL">تغيُرات غير طبيعية في المخ، والتي من الممكن أن تسبب مجموعة من الأعراض بما في ذلك: صداع، ارتباك/التباس، نوبات تشنجية وفقدان الرؤية المصحوب بنتائج التَّصوير بالرنين المغناطيسي (متلازمة اعتلال بيضاء الدماغ الخلفي القابلة للارتداد)</li><li dir="RTL">نوبة قلبية</li><li dir="RTL">التهاب الأغشية المخاطية بالفم (التهاب الفم).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا </strong><strong>(قد تُؤثر على ما يصل إلى شخص واحد من كل </strong><strong>10000 شخص</strong><strong>)</strong></p><ul><li dir="RTL">ارتفاع مستويات الحديد في الدَّم</li><li dir="RTL">توقف القلب عن ضخ الدم (سكتة قلبية)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong><strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</strong><strong>)</strong></p><ul><li dir="RTL">عدوى</li><li dir="RTL">تدمير خلايا الدَّم الحمراء (فقر الدَّم الانحلالي الإيجابي في اختبار كومبس)</li><li dir="RTL">ارتفاع بعض الإنزيمات (الأميلاز)</li><li dir="RTL">مجموعة من الأعراض التي تحدث إصابة بها عند وجود كمية كبيرة من الهرمون المضاد لإدرار البول (ADH) في الجسم مثل احتباس الماء واختلال توازن الإليكتروليتات وانخفاض مستوى الصوديوم بالدم (يسمى نقص صوديوم الدم أو التسمم بالماء)</li><li dir="RTL">جفاف</li><li dir="RTL">انخفاض مستويات الإليكتروليتات بالدم (البوتاسيوم، فوسفات، الكالسيوم)</li><li dir="RTL">ارتفاع مستوى حمض اليوريك بالدَّم، وهو أحد الفضلات الناجمة عن هضم الطعام</li><li dir="RTL">تقلصات عضلية (تكزز)</li><li dir="RTL">سكتة دماغية</li><li dir="RTL">فقدان حاسة التَّذوق</li><li dir="RTL">التهاب الأوعية الدَّموية في المخ</li><li dir="RTL">آلاَمٌ بَارِقَة مفاجئة من الرقبة تمتد إلى الظهر ثم الساقين عند الانحناء إلى الأمام (علامة على الإصابة بداء ليرميت)</li><li dir="RTL">انْضِغاطِ النُّخاعِ الشوكي (اعتلال نخاعي)</li><li dir="RTL">تلف الأعصاب التي تتحكم في وظائف الجسم اللاإرادية (قد تؤثر على ضغط الدم، التحكم في درجة الحرارة، الهضم، وظائف المثانة)</li><li dir="RTL">عدم وضوح الرؤية</li><li dir="RTL">عمى الألوان</li><li dir="RTL">فقدان الرؤية (فقدان البصر)</li><li dir="RTL">التهاب العصب البصري</li><li dir="RTL">تورم حول العصب المسؤول عن الرؤية (وَذَمَةُ حُلَيمَةِ العَصَبِ البَصَرِيّ)</li><li dir="RTL">تصبغ الشبكية (نسيج حسي متعدد الطبقات يبطن الجزء الخلفي من العين المسؤول عن الرؤية)</li><li dir="RTL">ضجيج بالأذن، مثل رنين أو طنين أو هدير أو نقر</li><li dir="RTL">الصمم</li><li dir="RTL">&nbsp;مشاكل في القلب</li><li dir="RTL">مجموعة من العلامات بما في ذلك فَقْرُ الدَّمِ الانْحِلالِيّ (تدمير خلايا الدم الحمراء) والفشل الكلوي وانخفاض تعداد الصفائح الدموية (أحد أنواع خلايا الدم الذي يساعد على تجلط الدم) (متلازمة انحلال الدم اليوريمي)</li><li dir="RTL">شحوب أصابع اليدين وأصابع القدم وتحول لونها إلى اللون الأزرق (ظاهرة رينود)</li><li dir="RTL">الشعور بالإعياء (غثيان) وقئ</li><li dir="RTL">فقدان الشهية</li><li dir="RTL">&nbsp;فُواق</li><li dir="RTL">إسهال</li><li dir="RTL">زيادة إنزيمات في الدم، مما قد يكون علامة على وجود تلف بالكبد</li><li dir="RTL">تجلط في الرئتين</li><li dir="RTL">طفح جلدي</li><li dir="RTL">تساقط الشعر (ثعلبة)</li><li dir="RTL">تقلصات عضلية</li><li dir="RTL">انخفاض أو فقدان وظائف الكُلى بشكل كامل</li><li dir="RTL">ضعف، فقدان الطاقة</li><li dir="RTL">احمرار والتهاب وتورم في الجلد وألم في منطقة الحقن نتيجة للحقن في النسيج المحيط بدلًا من الحقن في الوريد</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا يُخزَّن في درجة حرارة تتعدى 25 درجة مئوية.</p><p dir="RTL">لا تقم بتبريده أو تجميده.</p><p dir="RTL">احتفظ بالزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونية والزجاجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت علامات تلف واضحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كل مللي لتر من المحلول على 0.5 مجم من سِيسْبلاتين.</p><p dir="RTL">تحتوي الزجاجة بحجم 20 مللي لترًا على 10 مجم سِيسْبلاتين، تحتوي الزجاجة بحجم 50 مللي لترًا على 25 مجم سِيسْبلاتين و</p><p dir="RTL">تحتوي الزجاجة بحجم 100 مللي لتر على 50 مجم سِيسْبلاتين.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><u>المادة الفعالة هي</u> عقار سِيسْبلاتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>المكونات الأخرى هي</u> كلوريد الصوديوم، حمض الهيدروكلوريك المخفف وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار سِيسْبلاتين عبارة عن محلول صافٍ عديم اللون يميل إلى اللون الأصفر مُعد للتسريب، ويتوفر في عبوات زجاجية للحقن.</p><p dir="RTL">عبوة بها زجاجة حقن واحدة بحجم 20 مللي لترًا، تحتوي كل زجاجة حقن على 10 مجم سِيسْبلاتين.</p><p dir="RTL">عبوة بها زجاجة حقن واحدة بحجم 50 مللي لترًا، تحتوي كل زجاجة حقن على 25 مجم سِيسْبلاتين.</p><p dir="RTL">عبوة بها زجاجة حقن واحدة بحجم 100 مللي لتر، تحتوي كل زجاجة حقن على 50 مجم سِيسْبلاتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعبأ الزجاجات مع أو بدون غلاف بلاستيكي واقٍ (OncoSafe&reg;).</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة إيبيفيه فارما المحدودة Nfg. شراكة محدودة 4866 أونتراخ، النمسا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CISPLATIN 0.5 mg/ml – Concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 0.5 mg cisplatin.

1 vial of 20 ml concentrate for solution for infusion contains 10 mg cisplatin.
1 vial of 50 ml concentrate for solution for infusion contains 25 mg cisplatin.
1 vial of 100 ml concentrate for solution for infusion contains 50 mg cisplatin.

Excipient(s) with known effect
Each ml concentrate for solution contains 3,54 mg 
1 vial of 20 ml concentrate for solution for infusion contains 71 mg sodium
1 vial of 50 ml concentrate for solution for infusion contains 177 mg sodium
1 vial of 100 ml concentrate for solution for infusion contains 354 mg sodium

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion

The concentrate is a clear and colourless to yellowish solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours: testicular carcinoma (palliative and curative poly-chemotherapy) and ovary carcinoma (stages III and IV), and head and neck squamous-cell epithelioma (palliative therapy).</p><p>In the treatment of small cell lung carcinoma.</p><p>In the treatment of advanced non-small cell lung carcinoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p><strong>Adults and children:</strong></p><p><strong>&nbsp;</strong></p><p>The cisplatin dosage depends on the primary disease, the expected reaction, and on whether cisplatin is used for monotherapy or as a component of a combination chemotherapy. The dosage directions are applicable for both adults and children. For recommendations on the dosage applicable, based on the diagnosis and the clinical condition, the current medical literature should be consulted.</p><p>&nbsp;</p><p>For <u>monotherapy</u>, the following two dosage regimens are recommended:</p><p>Single dose of 50 to 120&nbsp;mg/m&sup2; body surface every 3 to 4&nbsp;weeks;</p><p>15 to 20&nbsp;mg/m&sup2;/day for five days, every 3 to 4&nbsp;weeks.</p><p>If cisplatin is used in <u>combination chemotherapy</u>, the dose of cisplatin must be reduced. A typical dose is 20&nbsp;mg/m&sup2; or more once every 3 to 4&nbsp;weeks unless in the combination therapy of small-cell and non-small-cell lung carcinoma, in which a typical dose of 80 mg/m&sup2; is administered.</p><p>&nbsp;</p><p>Further dosage recommendations are to be based upon current medical insights, to be obtained from the literature or/and the appropriate working parties.</p><p>&nbsp;</p><p>For warnings and precautions to be considered prior to the start of the next treatment cycle, see section 4.4.</p><p>&nbsp;</p><p>In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately.</p><p>&nbsp;</p><p>Method of administration</p><p>CISPLATIN 0.5mg/ml concentrate for solution for infusion} is to be diluted before use (see section 6.6.).</p><p>&nbsp;</p><p>The diluted solution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided (see section 6.2.).</p><p>&nbsp;</p><p>The cisplatin solution for infusion prepared according to instructions (see section 6.6.) should be administered by intravenous infusion over a period of 6 to 8 hours.</p><p>&nbsp;</p><p>Adequate hydration must be maintained from 2 to 12 hours prior to administration until minimum 6 hours after the administration of cisplatin. Hydratation is necessary to cause sufficient diuresis during and after treatment with cisplatin. It is realised by intravenous infusion of one of the following solutions:</p><p>sodium chloride solution 0.9%;</p><p>mixture of sodium chloride solution 0.9% and glucose solution 5% (1:1).</p><p>Hydration <u>prior</u> to treatment with cisplatin:</p><p>Intravenous infusion of 100 to 200ml/hour for a period of 6 to 12 hours.</p><p>Hydration <u>after</u> termination of the administration of cisplatin:</p><p>Intravenous infusion of another 2 litres at a rate of 100 to 200 ml per hour for a period of 6 to 12 hours.</p><p>&nbsp;</p><p>Forced diuresis may be required should the urine secretion be less than 100 to 200 ml/hour after hydration. Forced diuresis may be realised by intravenously administering 37.5g mannitol as a 10% solution (375 ml mannitol solution 10%), or by administration of a diuretic if the kidney functions are normal. The administration of mannitol or a diuretic is also required when the administrated cisplatin dose is higher than 60 mg/m<sup>2</sup> of body surface.</p><p>&nbsp;</p><p>It is necessary that the patient drinks large quantities of liquids for 24 hours after the cisplatin infusion to ensure adequate urine secretion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or other platinum containing compounds, or to any of the excipients listed in section 6.1
-	in dehydrated condition (pre- and post-hydration is required to prevent serious renal dysfunction);
-	with myelosuppression;
-	pre-existing renal impairment or hearing impairment due to the fact that cisplatin is nephrotoxic and neurotoxic (in particular ototoxic). These toxicities may be cumulative if disorders of this type pre-exist.
-	breastfeeding (see section 4.6.)
-	in combination with yellow fever vaccine and phenytoin in prophylactic use (See section 4.5.).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cisplatin reacts with metallic aluminum to form a black precipitate of platinum. All aluminum containing IV sets, needles, catheters and syringes should be avoided.</p><p>&nbsp;</p><p>Cisplatin must be administered under close supervision by a qualified doctor specialized in the use of chemotherapeutic agents.</p><p>&nbsp;</p><p>Appropriate monitoring and management of the treatment and its complications are only possible if adequate diagnosis and exact treatment conditions are available.</p><p>&nbsp;</p><p>Before, during and after administration of cisplatin, the following parameters resp. organ functions must be determined:</p><p>- renal function;</p><p>- hepatic function;</p><p>- haematopoiesis functions (number of red and white blood cells and blood platelets);</p><p>- serum electrolytes (calcium, sodium, potassium, magnesium).</p><p>These examinations must be repeated every week over the entire duration of the treatment with cisplatin.</p><p>&nbsp;</p><p>Repeating administration of cisplatin must be delayed until normal values are achieved for the following parameters:</p><p>- serum creatinine &le;130 &mu;mol/l resp. 1.5 mg/dl</p><p>- urea &lt;25 mg/dl</p><p>- white blood cells &gt;4.000/&mu;l resp. &gt;4.0 x 10<sup>9</sup>/l</p><p>- blood platelets &gt;100.000/&mu;l resp. &gt;100 x 10<sup>9</sup>/l</p><p>- audiogram: results within the normal range.</p><p>&nbsp;</p><p><u>Nephrotoxicity</u></p><p>Cisplatin causes severe cumulative nephrotoxicity which may be potentiated by other substances (please refer to section 4.5). A urine output of 100 mL/hour or greater will tend to minimize cisplatin nephrotoxicity. This can be accomplished by pre-hydration with 2 liters of an appropriate intravenous solution, and similar post cisplatin hydration (recommended 2,500 mL/m2/24 hours). If vigorous hydration is insufficient to maintain adequate urinary output, an osmotic diuretic may be administered (eg, mannitol).</p><p>&nbsp;</p><p><u>Neuropathies</u></p><p>Severe cases of neuropathies have been reported. These neuropathies may be irreversible and may manifest by paraesthesia, areflexia and a proprioceptive loss and a sensation of vibrations. A loss of motor function has also been reported. A neurologic examination must be carried out at regular intervals.</p><p>&nbsp;</p><p><u>Ototoxicity</u></p><p>Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin 50mg/m2, and is manifested by tinnitus and/or hearing loss in the high frequency range (4000 to 8000Hz). Decreased ability to hear conversational tones may occur occasionally. Ototoxic effect may be more pronounced in children receiving cisplatin. Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated doses; however, deafness after initial dose of cisplatin has been reported rarely. Ototoxicity may be enhanced with prior simultaneous cranial irradiation and may be related to peak plasma concentration of cisplatin. It is unclear whether cisplatin induced ototoxicity is reversible. Careful monitoring by audiometry should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin. Vestibular toxicity has also been reported (see section 4.8).</p><p>&nbsp;</p><p><u>Allergic phenomena</u></p><p>As with other platinum-based products, hypersensitivity reactions appearing in most cases during perfusion may occur, and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment. Cross reactions, sometimes fatal, have been reported with all the platinum compounds (see section 4.3 and section 4.8).</p><p>&nbsp;</p><p><u>Hepatic function and hematological formula</u></p><p>The hematological formula and the hepatic function must be monitored at regular intervals.</p><p>&nbsp;</p><p><u>Carcinogenic potential</u></p><p>In humans, in rare cases the appearance of acute leukemia has coincided with use of cisplatin, which was in general associated with other leukemogenic agents.</p><p>&nbsp;</p><p>Cisplatin is a bacterial mutagen and causes chromosome aberrations in cultures on animal cells. Carcinogenicity is possible but has not been demonstrated. Cisplatin is teratogenic and embryotoxic in mice.</p><p>&nbsp;</p><p><u>Injection site reactions</u></p><p>Injection site reactions may occur during the administration of cisplatin. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for extravasation reactions is unknown at this time.</p><p>&nbsp;</p><p><u>Warning</u></p><p>This cytostatic agent has a more marked toxicity than is usually found in antineoplastic chemotherapy.</p><p>&nbsp;</p><p>Renal toxicity, which is above-all cumulative, is severe and requires particular precautions during administration (see section 4.2 and section 4.8).</p><p>&nbsp;</p><p>Prophylactic administration of an anti-emetic may be effective in alleviating or preventing nausea and vomiting.</p><p>&nbsp;</p><p>The liquid loss caused by vomiting and diarrhoea must be compensated.</p><p>&nbsp;</p><p>&nbsp;</p><p>Nausea and vomiting may be intense and require adequate antiemetic treatment.</p><p>&nbsp;</p><p>Close supervision must also be carried out with regard to ototoxicity, myelodepression and anaphylactic reactions (see section 4.8 Undesirable effects).</p><p>&nbsp;</p><p>Cisplatin has been shown to be mutagenic. It may also have an anti-fertility effect. Other anti-neoplastic substances have been shown to be carcinogenic and this possibility should be borne in mind in long term use of cisplatin.</p><p>&nbsp;</p><p><u>Warning</u></p><p><u>Preparation of the intravenous solution</u></p><p>As with all other potentially toxic products, precautions are essential when handling the cisplatin solution. Skin lesions are possible in the event of accidental exposure to the product. It is advisable to wear gloves. In the event the cisplatin solution comes into contact with the skin or mucous membranes, wash the skin or mucous membranes vigorously with soap and water.</p><p>&nbsp;</p><p>Conforming to the procedures appropriate for the manipulation and elimination of cytostatic agents is recommended.</p><p>&nbsp;</p><p>Before administering the solution to the patient, verify the clarity of the solution and the absence of particles.</p><p>&nbsp;</p><p>This medicinal product contains 71 mg sodium per 20ml vial, equivalent to 3.55% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>This medicinal product contains 177 mg sodium per 50ml vial, equivalent to 8.85% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>This medicinal product contains 354 mg sodium per 100ml vial, equivalent to 17.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Nephrotoxic substances</u></p><p>Concomitant administration of nephrotoxic (e.g. cephalosporins, aminoglycosides, amphotericin B or contrast media) or ototoxic (e.g. aminoglycosides) medicinal products will potentiate the toxic effect of cisplatin on the kidneys. During or after treatment with cisplatin caution is advised with predominantly renally eliminated substances, e.g. cytostatic agents such as bleomycin and methotrexate, because of potentially reduced renal elimination.</p><p>&nbsp;</p><p>The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.</p><p>&nbsp;</p><p>Reduction of the blood&rsquo;s lithium values was noticed in a few cases after treatment with cisplatin combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.</p><p>&nbsp;</p><p>The occurrence of nephrotoxicity caused by cisplatin may be intensified by concomitant treatment with antihypertensives containing furosemide, hydralazine, diazoxide, and propranolol.</p><p>It may be required to adjust the dose of allopurinol, colchicine, probenecid, or sulfinpyrazone if used together with cisplatin, since cisplatin causes an increase in serum uric acid concentration.</p><p>Simultaneous use of ifosfamide causes increased protein excretion.</p><p><u>&nbsp;</u></p><p><u>Ototoxic substances</u></p><p>Concomitant administration of ototoxic (e.g. aminoglycosides, loop diuretics) medicinal products will potentiate the toxic effect of cisplatin on auditory function. Except for patients receiving doses of cisplatin exceeding 60 mg/m2, whose urine secretion is less than 1000 ml per 24 hours, no forced diuresis with loop diuretics should be applied in view of possible damage to the kidney tract and ototoxicity.</p><p>&nbsp;</p><p>Ifosfamide may increase hearing loss due to cisplatin.</p><p>&nbsp;</p><p><u>Attenuated live vaccines</u></p><p>Yellow fever vaccine is strictly contraindicated because of the risk of fatal systemic vaccinal disease (see section 4.3). In view of the risk of generalized illness, it is advisable to use an inactivated vaccine if available.</p><p>&nbsp;</p><p>Use of living virus vaccinations is not recommended given within three months following the end of cisplatin treatment.</p><p>&nbsp;</p><p><u>Oral anticoagulants</u></p><p>In the event of simultaneous use of oral anticoagulants, it is advisable regularly to check the INR.</p><p>&nbsp;</p><p><u>Antihistamines, Phenothiazines and others</u></p><p>Simultaneous use of antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides may mask ototoxicity symptoms (such as dizziness and tinnitus).</p><p>&nbsp;</p><p><u>Anticonvulsive substances</u></p><p>Serum concentrations of anticonvulsive medicines may remain at sub-therapeutic levels during treatment with cisplatin.</p><p>&nbsp;</p><p>Cisplatin may reduce the absorption of phenytoin resulting in reduced epilepsy control when phenytoin is given as current treatment. During cisplatin therapy starting a new anticonvulsant treatment with phenytoin is strictly contraindicated (see section 4.3.).</p><p>&nbsp;</p><p><u>Pyridoxine + altretamine combination</u></p><p>During a randomized study of the treatment of advanced ovarian cancer, the response time was unfavorably affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin.</p><p>&nbsp;</p><p><u>Paclitaxel</u></p><p>Treatment with cisplatin prior to an infusion with paclitaxel may reduce the clearance of paclitaxel by 33% and therefore can intensify neurotoxicity.</p><p>&nbsp;</p><p><u>Other </u></p><p>Simultaneous use of myelosuppressives or radiation will boost the effects of cisplatin&rsquo;s myelosuppressive activity.</p><p>&nbsp;</p><p>Cisplatin given in combination with bleomycin and vinblastin can lead to a Raynaud-phenomenon.</p><p>&nbsp;</p><p>In a study of cancer patients with metastatic or advanced tumors, docetaxel in combination with cisplatin induced more severe neurotoxic effects (dose-related and sensoric) than either medicinal product as a single agent in similar doses.</p><p>&nbsp;</p><p>Chelating agents like penicillamine may diminish the effectiveness of cisplatin.</p><p>In concomitant use of cisplatin and ciclosporin the excessive immunosuppression with risk of lymphoproliferation is to be taken into consideration.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of cisplatin in pregnant women, but based on its pharmacological properties Cisplatin is suspected to cause serious birth defects.</p><p>Studies in animals have shown reproductive toxicity and transplacental carcinogenicity (see section 5.3.). Cisplatin should not be used during pregnancy unless the clinical condition of the woman requires treatment with cisplatin.</p><p>&nbsp;</p><p>Breastfeeding</p><p>Cisplatin is excreted in human milk. Breastfeeding during the therapy is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p><strong>Both male and female patients must use effective contraceptive methods to prevent conception and/or reproduction during and for at least 6 months after the treatment with Cisplatin. </strong>Genetic consultation is recommended if the patient wishes to have children after ending the treatment. Since a treatment with cisplatin may cause irreversible infertility, it is recommended that men, who wish to become fathers in the future, ask for advice regarding cryoconservation of their sperm prior to the treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed.</p><p>Due to the possible side effects (like nephrotoxicity) cisplatin has minor or moderate influence on the ability to drive and use machines. Patients who suffer from these effects (eg feeling sleepy or vomiting) must avoid driving and operating machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects depend on the used dose and may have cumulative effects.</p><p>&nbsp;</p><p>The most frequently reported adverse events (&gt;10%) of Cisplatin were haematological (leukopenia, thrombocytopenia and anaemia), gastrointestinal (anorexia, nausea, vomiting and diarrhoea), ear disorders (hearing impairment), renal disorders (renal failure, nephrotoxicity, hyperuricaemia) and fever.</p><p>&nbsp;</p><p>Serious toxic effects on the kidneys, bone marrow and ears have been reported in up to about one third of patients given a single dose of cisplatin; the effects are generally dose-related and cumulative. Ototoxicity may be more severe in children.</p><p>&nbsp;</p><p>The list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories:</p><p>very common (&ge; 1/10), common (&ge; 1/100, &lt; 1/10), uncommon (&ge;1/1000, &lt; 1/100), rare (&ge; 1/10000, &lt;&nbsp;1/1000), very rare (&lt;&nbsp;1/10000), and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table of Adverse Drug Events reported during clinical or post-marketing experience (MedDRA terms)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Infection<sup>a</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Neoplasm benign, malignant, and unspecified </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Acute leukemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Bone marrow failure, thrombocytopenia, leukopenia, anemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Coombs positive hemolytic anemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Anaphylactoid<sup>b</sup> reactions</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Blood amylase increased, inappropriate antidiurectic hormone secretion</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Hyponatremia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Hypercholesterolaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Increased blood iron</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Hypomagnesemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Dehydration, hypokalemia, hypophosphatemia, hyperuricemia, hypocalcemia, tetany</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Convulsion, neuropathy peripheral, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Cerebrovascular accident, hemorrhagic stroke, ischemic stroke, ageusia, cerebral arteritis, Lhermitte&rsquo;s sign, myelopathy, autonomic neuropathy</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred, color blindness acquired, blindness cortical, optic neuritis, papilledema, retinal pigmentation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Ototoxicity</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Tinnitus, deafness</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Arrhythmia, bradycardia, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac disorder</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Venous thromboembolism</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Thrombotic microangiopathy (hemolytic uremic syndrome), Raynaud&rsquo;s phenomenon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea, pneumonia and respiratory failure</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Metallic setting on the gums</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Vomiting, nausea, anorexia, hiccups, diarrhea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic enzymes increased, blood bilirubin increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Rash, alopecia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Muscle spasms</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Renal failure acute, renal failure<sup>c</sup>, renal tubular disorder</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Abnormal spermatogenesis and ovulation, and painful gynaecomastia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia, malaise, injection site extravasation<sup>d</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>a: Infectious complications have led to death in some patients.</p><p>b: Symptoms reported for anaphylactoid reaction included amongst others facial edema, wheezing,bronchospasm, tachycardia, and hypotension in the AE frequency table.</p><p>c: Elevations in BUN and creatinine, serum uric acid, and/or a decrease in creatinine clearance are subsumed</p><p>under renal insufficiency/failure.</p><p>d: Local soft tissue toxicity including tissue cellulitis, fibrosis, and necrosis (common) pain (common), oedema (common) and erythema (common) as the result of extravasation.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CAUTION IS ESSENTIAL IN ORDER TO PREVENT AN INADVERTENT OVERDOSE.</strong></p><p>&nbsp;</p><p>An acute overdose of cisplatin may result in renal failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, untreatable nausea and vomiting and/or neuritis. An overdose may be fatal.</p><p>&nbsp;</p><p>There is no specific antidote in the event of a cisplatin overdose. Even if hemodialysis is initiated 4 hours after the overdose it has little effect on the elimination of cisplatin from the body due to a strong and rapid fixation of cisplatin to proteins.</p><p>&nbsp;</p><p>Treatment in the event of an overdose consists of general supportive measures.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents / Platinum compounds ATC code: L01XA01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Cisplatin is an anorganic substance containing a heavy metal [cis-diamminedichloroplatinum(II)]. This substance inhibits the DNA synthesis by realising transverse connections within and between the DNA strings. The protein and RNA synthesis is inhibited to a lesser extent.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Although the primary activity of cisplatin seems to be the inhibition of DNA synthesis, the antineoplastic process includes other activities, such as enlargement of the tumour immunogenicity. Cisplatin&rsquo;s oncolytic functions can be compared to the functions of alkylating substances. Cisplatin also offers immunosuppressive, radiosensitising and antibacterial features.</p><p>&nbsp;</p><p>Cisplatin does not seem to be cell cycle specific.</p><p>&nbsp;</p><p>The cytotoxic activities of cisplatin are caused by binding all DNA bases, with a preference for the N-7 position of guanine and adenosine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>After intravenous administration, cisplatin is rapidly distributed among all tissues. Following cisplatin doses of 20 to 120&nbsp;mg/m&sup2;, the concentrations of platinum are highest in liver, prostate and kidney, somewhat lower in bladder, muscles, testicle, pancreas and spleen and lowest in bowel, adrenal, heart, lung, cerebrum and cerebellum.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Over 90% of the total plasma cisplatin is bounded with protein after two hours following the administration. This process may be irreversible. The protein-bounded part is not antineoplastic active. Cisplatin is non-linearly pharmacokinetic. Cisplatin is converted by a non-enzymatic process into one or more metabolites.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Elimination from the plasma is realised in two phases after intravenous bolus injection of 50‑100 mg/m2 of cisplatin. The following half-life period have been registered for humans:</p><p>&nbsp;</p><p>t &frac12; (distribution): 10-60 minutes</p><p>t &frac12; (terminal): approximately 2-5 days</p><p>&nbsp;</p><p>The considerable protein binding of the total platinum contents results in an extended or incomplete excretion phase with cumulative urine secretion ranging from 27 to 45% of the administered dose in a period from 84 to 120 hours. An extended infusion results in the urine secretion of a larger part of the dose. The faecal secretion is minimal, and small amounts of platinum can be traced in the gallbladder and the large intestine. Dysfunctional kidneys increase the plasma half-life period, which may also increase theoretically in the presence of ascites caused by the highly protein binding activities of cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chronic toxicity:</p><p>&nbsp;</p><p>Chronic toxicity models indicate kidney damage, bone marrow depression, gastro-intestine disorders and ototoxicity.</p><p>&nbsp;</p><p>Mutagenity and carcinogenity:</p><p>&nbsp;</p><p>Cisplatin is mutagenic in numerous in vitro and in vivo tests (bacterial test systems and chromosome defects in animal cells and tissue cultures). Long term studies of cisplatin on mice and rats evidenced the carcinogenic effects.</p><p>&nbsp;</p><p>Reproductive toxicity:</p><p>&nbsp;</p><p>Fertility: Gonadal suppression resulting in amenorrhoea or azoospermia may be irreversible and cause definitive infertility.</p><p>&nbsp;</p><p>Studies in rats showed that exposure during pregnancy produces tumours in the adult offspring.</p><p>&nbsp;</p><p>Pregnancy and lactation: Cisplatin is embryotoxic and teratogenic for mice and rats, and defects have been reported for both species. Cisplatin was found in the milk.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride</p><p>Hydrochloric acid, dilute</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cisplatin reacts with aluminium which results in production of a black platinum precipitate. Therefore any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>The cisplatin 0.5&nbsp;mg/ml concentrate must not be diluted with glucose solution 5% alone or mannitol solution 5% alone, but only with the mixtures containing additionally sodium chloride as stated in section 6.6.</p><p>&nbsp;</p><p>Antioxidants (such as sodium metabisulphite), bicarbonates (sodium bicarbonate), sulfates, fluorouracil and paclitaxel may inactivate cisplatin in infusion systems.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medicinal product as packaged for sale:
2 years

Solution for infusion after dilution (see section 6.6): 
Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8°C when protected from light for solutions with a final cisplatin concentration of 0.1 mg/ml after dilution of the cisplatin 0.5 mg/ml concentrate with one of the following solutions:
sodium chloride solution 0.9%;
mixture of sodium chloride solution 0.9% and glucose solution 5% (1:1);
mixture of sodium chloride solution 0.9% and mannitol solution 5% (1:1).

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution / dilution (etc) has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicinal product as packaged for sale:</p><p>Do not store above 25&nbsp;&deg;C. Do not refrigerate or freeze. Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber type&nbsp;I glass vial with chlorobutyl rubber stopper with aluminium overseal.</p><p>&nbsp;</p><p>Packs of</p><p>1 vial containing 20 ml (10mg) concentrate for solution for infusion each.</p><p>1 vial containing 50 ml (25mg) concentrate for solution for infusion each.</p><p>1 vial containing 100 ml (50mg) concentrate for solution for infusion each.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p>The vials are packed with or without a protective plastic overwrap (OncoSafe&reg;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CISPLATIN is to be diluted before use. For preparation of solution for infusion, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided (see section 6.2.).</p><p>Preparation of solution for infusion must take place in aseptic conditions.</p><p>For dilution of the concentrate, one of the following solutions should be used:</p><p>sodium chloride solution 0.9%;</p><p>mixture of sodium chloride solution 0.9% and glucose solution 5% (1:1) (resulting final concentrations: sodium chloride 0.45%, glucose 2.5%).</p><p>Should hydration prior to the treatment with cisplatin be impossible, the concentrate may be diluted with:</p><p>mixture of sodium chloride solution 0.9% and mannitol solution 5% (1:1) (resulting final concentrations: sodium chloride 0.45%, mannitol 2.5%).</p><p>&nbsp;</p><p>Preparation of cisplatin solution for infusion:</p><p>The required amount (dose) of the cisplatin concentrate 0.5&nbsp;mg/ml calculated according to the instructions in section 4.2. should be diluted in 1-2 litres of one of the above mentioned solutions.</p><p>&nbsp;</p><p>The diluted solution should be administered only by intravenous infusion (see section 4.2.).</p><p>Only clear and colourless to yellowish solutions without visible particles should be used.</p><p>&nbsp;</p><p>For single use only.</p><p>&nbsp;</p><p>Cytotoxic agents should be prepared for administration only by personnel who have been trained in the safe handling of the preparation.</p><p>&nbsp;</p><p>Refer to local cytotoxic handling guidelines.</p><p>&nbsp;</p><p>As any other cytotoxic agent, cisplatin should be used with extreme caution: gloves, face masks and protective clothing are required and vital. Cisplatin should be processed under a protective hood, if possible. Contact with skin and/or mucous membranes must be avoided. Pregnant hospital employees should not work with cisplatin.</p><p>&nbsp;</p><p>Skin contact: Rinse with large quantities of water. Apply an ointment if you have a temporary burning feeling. (Note: Some persons are sensitive to platinum and may experience a skin reaction).</p><p>&nbsp;</p><p>In the event of spillage, operators should put on gloves and mop up the spilled material with a sponge kept in the area for that purpose. Rinse the area twice with water. Put all solutions and sponges into a plastic bag and seal it. In the case of spillage all items coming into contact with Cisplatin should be handled and disposed in accordance to local cytotoxic guidelines.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>